We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MedImmune and WuXi AppTec Announce Joint Venture
News

MedImmune and WuXi AppTec Announce Joint Venture

MedImmune and WuXi AppTec Announce Joint Venture
News

MedImmune and WuXi AppTec Announce Joint Venture

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MedImmune and WuXi AppTec Announce Joint Venture"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MedImmune will provide technical and development expertise, while WuXi AppTec will provide local regulatory, manufacturing, pre-clinical and clinical trial support.  When undertaking clinical trial development in China, the government requires local manufacture of medicines that have not been approved in other markets.

“We are pleased to partner with WuXi AppTec, a company with strong leadership in the Chinese pharmaceutical R&D sector, to help us address the healthcare needs of Chinese patients through the co-development of MEDI5117,” said Bahija Jallal, Executive Vice President, Research & Development, MedImmune.  “This strategic partnership will enable us to establish a leadership presence in developing novel biologics in China, complementing AstraZeneca’s investment in this important emerging market.”

The joint venture will control the development of MEDI5117 for autoimmune and inflammatory diseases in China, and the two companies will have equal ownership in the joint venture.  AstraZeneca / MedImmune will have the option to acquire the full rights to commercialize MEDI5117; otherwise, the joint venture will have the right to commercialize the product.  WuXi AppTec will earn revenue based on services provided to the joint venture.  MedImmune will receive various milestone payments as the program progresses.

“WuXi is delighted to work with MedImmune, an innovative biologics company, to develop and manufacture a novel product for first use in China,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec.  “WuXi is working to build long-term drug development partnerships with leading biopharmaceutical companies like MedImmune to help accelerate the development of novel medicines for the large and rapidly growing Chinese pharmaceutical market.”

Today’s announcement supports AstraZeneca’s ongoing commitment to collaborating across Asia in ways that maximize the scientific and local knowledge of its partners and tap into the region’s strong history of innovation.

The Chinese government’s focus on healthcare reform, along with its investment in improving healthcare infrastructure and expanding medical insurance coverage, are expected to continue to drive growth and demand for quality medicines over the long term.  China also continues to increase its biomedical R&D investment, fuelled by sustained GDP growth.  The Chinese pharmaceutical market grew from $10 billion in 2004 to $41 billion in 2010 and, according to IMS Health, is projected to grow to over $100 billion by 2014.

Advertisement